Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | FFAR3 | O14843 | 12/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064866 | 0.87 | FFAR3 (0.76) | KDM4EFFAR3SMN1; SMN2 | |
| SCHEMBL3263495 | 0.86 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL3263202 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| O-Tolylamine SCHEMBL5315045 | 0.80 | FFAR3 (0.52) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL5202041 | 0.77 | FFAR3 (0.76) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL5197527 | 0.77 | FFAR3 (0.60) | ALDH1A1KDM4EFFAR3SMN1; SMN2LMNA | |
| SCHEMBL14010782 | 0.73 | FFAR3 (0.63) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 | |
| SCHEMBL3004453 | 0.73 | KDM4E (0.64) | ALDH1A1KDM4ESMN1; SMN2LMNATSHR | |
| SCHEMBL2998553 | 0.73 | SMN1; SMN2 (0.72) | ALDH1A1KDM4ESMN1; SMN2LMNATSHR | |
| SCHEMBL15866579 | 0.73 | FFAR3 (0.62) | ALDH1A1KDM4EMAPTFFAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |